Compare Apple Inc (AAPL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Merck & Co., Inc. — how do they compare? Apple Inc trades at $304.78 (market cap $4.45T), while Merck & Co., Inc. trades at $130.38 (market cap $321.77B). The key difference: Apple Inc is far larger — about 13.8× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| AAPL | MRK | |
|---|---|---|
Market Cap | $4.45T | $321.77B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $131.84 |
52-Week Low | $224.90 | $77.60 |
Enterprise Value | $4.47T | $368.53B |
Dividend Yield | 0.35% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and support near $306. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.98. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Recent news highlights AI potential through a partnership with Alphabet's Gemini, but store closures and union disputes pose headwinds.
Outlook remains positive with a consensus price target of $337.63, implying 9.5% upside, supported by robust cash flow and a 63.6% buy rating from analysts. Risks include weaker iPhone sales, regulatory fines, and competitive pressures in AI. The stock offers growth potential but requires monitoring of execution risks and macroeconomic trends.
Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.
The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
